Zepbound, a medication produced by Eli Lilly & Co., has received the green light from the Food and Drug Administration for the management of obstructive sleep apnea in adults with obesity. This marks Zepbound as the first prescription drug given the go-ahead for this specific purpose. The FDA recommends combining Zepbound with a reduced-calorie diet and increased physical activity for optimal results. Obstructive sleep apnea, a condition characterized by airway blockage leading to breathing difficulties during sleep, is more prevalent in individuals who are overweight. Studies have shown that Zepbound can help alleviate sleep apnea symptoms by promoting weight loss. In clinical trials involving adults with obesity and moderate to severe sleep apnea, those treated with Zepbound experienced significant improvements in breathing complications compared to a placebo group. This approval is being heralded as a breakthrough for individuals struggling with sleep apnea. The importance of maintaining a healthy weight to manage sleep apnea has long been emphasized by healthcare professionals. Beyond the treatment of diabetes and obesity, weight loss drugs are being investigated for their potential benefits in addressing addiction and cancer. Initially approved by the FDA in November 2023 for weight loss, Zepbound, also known as tirzepatide, is posing a challenge to Novo Nordisk’s Wegovy. In March, Wegovy was approved by the FDA as a preventative measure against strokes, heart attacks, and other cardiovascular issues in overweight patients.